| HOME >> BIOLOGY >> TECHNOLOGY |
- The Irish government, over the period from 2000 to 2008, will have invested over EUR8 billion to accelerate the development of an indigenous science and technology base. A further EUR8.2 billion will be invested between 2006 and 2013.
- In the past five years a significant number of life science companies have been formed in Ireland and many are actively seeking capital to advance product development.
- Venture investing in the life science sector in Ireland has lagged behind other life science clusters in the US or Europe. Fountain is being established to fill this gap and capitalise on this opportunity.
About Fountain Healthcare Partners
Headquartered in Dublin, Fountain Healthcare Partners is Ireland's largest dedicated life science venture capital fund. A spin-out investment team from Elan Corporation's corporate venture capital group, Fountain launched its inaugural fund in 2008. Fountain will invest the majority of its capital in Europe with a primary focus on Ireland. Specific areas of interest to Fountain are specialty pharmaceuticals, biotechnology, medical devices and diagnostics. For more information please visit http://www.fh-partners.com.
The principals in Fountain are Dr Manus Rogan (Elan Corporation, GlaxoSmithKline), Aidan King (Bio-IB, Elan Corporation), Dr Ena Prosser (Enterprise Ireland, Elan Corporation) and Justin Lynch (LegendCare, Fyffes, Jones Group and NCB). The core team is also supported by world class Business and Scientific Advisory Boards.
Fountain's core team have over 60 years of venture investment and
operational experience in the life sciences industry, ma
'/>"/>
| SOURCE Fountain Healthcare Partners Copyright©2008 PR Newswire. All rights reserved |